EHA26: AvenCell’s AVC-201-01 switchable allogeneic CAR T offers early validation in AML

AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The R/R AML market has been shaped by biomarker-selected targeted therapies and emerging cellular approaches. Credit: L.D Danusha Tharangani/Shutterstock.com. At the European Hematology Association (EHA) 2026 Congress, updated results from the Phase Ia RevSTAR-123 trial were presented on June 13, 2026. The study evaluated AvenCell Therapeutics’ AVC-201-01, a first-in-class switchable allogeneic chimeric antigen receptor (CAR)-T cell therapy, in patients with interleukin-3 receptor alpha chain (CD123)-positive relapsed/refractory (R/R) or minimal residual…

Source: Clinical Trials Arena